Multicenter, Placebo-controlled, Parallel-randomized, Double-blind, Phase II Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of SHR-1314 Injection With Moderate to Severe Plaque Psoriasis in Adults
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Vunakizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 19 Mar 2020 Planned End Date changed from 15 Jun 2021 to 30 Dec 2020.
- 19 Mar 2020 Planned primary completion date changed from 30 Mar 2021 to 30 Jun 2020.
- 19 Mar 2020 Status changed from not yet recruiting to suspended.